Anavex Life Sciences Corp (AVXL)

[frrol]

The presentation should have been more forthright, yes. Scientific credibility at a research conference matters. The PR did not even say "co-" primary, though the deck did. The ADL miss should have been in the deck somewhere, and briefly mentioned as arguably irrelevant according to new guidance. Dizziness is a tolerability issue, though dizziness in a geriatric population can represent a safety issue if not truly manageable.

It's notable that sleep quality was an endpoint, but to date has not been mentioned. That is disappointing at this late hour. It is also tracked in the OLE. Looking forward to the OLE results, which could be coming soon.